Know Cancer

forgot password

Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer

Phase 2
18 Years
Not Enrolling
Biliary Tract Adenocarcinoma, Gallbladder Adenocarcinoma

Thank you

Trial Information

Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer

- The chemotherapy drugs are given twice every 28 days. This 28 day period is called a
cycle of study treatment.

- Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15.
Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of
each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of
each cycle.

- The following tests and procedures will be performed on day 1 and day 15 or each cycle:
physical examination; medical history; blood work; and urine test. A PET scan will be
repeated at the end of cycle 2 and CT scans will be repeated once every 8 weeks.

- Participants will continue to receive cycles of study treatment as long as their
disease does not progress and they are not experiencing any serious side effects.

Inclusion Criteria:

- Histologically confirmed, locally unresectable or metastatic biliary tract or
gallbladder adenocarcinoma. Patients must have at least one measurable lesion
outside prior radiation field.

- Zero to one prior chemotherapy for biliary tract or gallbladder cancer

- Age > 18 years

- ECOG performance status 0-2

- Life expectancy > 12 weeks

- Adequate organ and bone marrow function

Exclusion Criteria:

- Chemotherapy within past 3 weeks of initiation of therapy

- Pregnant or lactating women

- Clinically apparent central nervous system metastases or carcinomatous meningitis

- Biliary obstruction with inadequate drainage and total bilirubin > 2.5 mg/dL

- Concurrent malignancy of any site, except limited basal cell carcinoma or squamous
cell carcinoma of the skin or carcinoma in situ of the cervix

- Uncontrolled serious medical or psychiatric illness

- Pre-existing peripheral neuropathy of grade 2 or greater severity according to the
Common Terminology Criteria of the NCI (version 3.0)

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study

- Blood pressure of > 150/100 mmHg

- Unstable angina

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction or stroke within 6 months

- Clinically significant peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury with 28 days
prior to Day 1, anticipation of need for major surgical procedure during the course
of the study

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to day 1

- Serious, non-healing wound, ulcer, or bone fracture

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the progression free survival of GEMOX-B regimen in patients with unresectable or metastatic biliary tract and gallbladder adenocarcinoma.

Outcome Time Frame:


Safety Issue:


Principal Investigator

Andrew X. Zhu, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital


United States: Food and Drug Administration

Study ID:




Start Date:

May 2006

Completion Date:

Related Keywords:

  • Biliary Tract Adenocarcinoma
  • Gallbladder Adenocarcinoma
  • Avastin
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Gallbladder Neoplasms